We are independent & ad-supported. We may earn a commission for purchases made through our links.
Advertiser Disclosure
Our website is an independent, advertising-supported platform. We provide our content free of charge to our readers, and to keep it that way, we rely on revenue generated through advertisements and affiliate partnerships. This means that when you click on certain links on our site and make a purchase, we may earn a commission. Learn more.
How We Make Money
We sustain our operations through affiliate commissions and advertising. If you click on an affiliate link and make a purchase, we may receive a commission from the merchant at no additional cost to you. We also display advertisements on our website, which help generate revenue to support our work and keep our content free for readers. Our editorial team operates independently of our advertising and affiliate partnerships to ensure that our content remains unbiased and focused on providing you with the best information and recommendations based on thorough research and honest evaluations. To remain transparent, we’ve provided a list of our current affiliate partners here.

What Is Vildagliptin?

By Andy Josiah
Updated May 17, 2024
Our promise to you
WiseGeek is dedicated to creating trustworthy, high-quality content that always prioritizes transparency, integrity, and inclusivity above all else. Our ensure that our content creation and review process includes rigorous fact-checking, evidence-based, and continual updates to ensure accuracy and reliability.

Our Promise to you

Founded in 2002, our company has been a trusted resource for readers seeking informative and engaging content. Our dedication to quality remains unwavering—and will never change. We follow a strict editorial policy, ensuring that our content is authored by highly qualified professionals and edited by subject matter experts. This guarantees that everything we publish is objective, accurate, and trustworthy.

Over the years, we've refined our approach to cover a wide range of topics, providing readers with reliable and practical advice to enhance their knowledge and skills. That's why millions of readers turn to us each year. Join us in celebrating the joy of learning, guided by standards you can trust.

Editorial Standards

At WiseGeek, we are committed to creating content that you can trust. Our editorial process is designed to ensure that every piece of content we publish is accurate, reliable, and informative.

Our team of experienced writers and editors follows a strict set of guidelines to ensure the highest quality content. We conduct thorough research, fact-check all information, and rely on credible sources to back up our claims. Our content is reviewed by subject-matter experts to ensure accuracy and clarity.

We believe in transparency and maintain editorial independence from our advertisers. Our team does not receive direct compensation from advertisers, allowing us to create unbiased content that prioritizes your interests.

Vildagliptin is a substance used to treat diabetes mellitus type 2, more commonly known as type 2 diabetes. It is used for patients who cannot control their blood sugar, or glucose in their blood, with other anti-diabetic medicines. Swiss-based multinational pharmaceutical company Novartis International AG markets the drug under the trade name Galvus.

The medical condition that vildagliptin fights against is the most common form of diabetes. It is sometimes called adult onset diabetes to set it apart from type 1 diabetes, or juvenile diabetes. Either way, the presence of diabetes indicates the lack of the insulin hormone, which leads to an increase of blood sugar. Vildagliptin is introduced to increase the amount of two hormones named glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), which contribute to the control of the body's glucose level. The anti-diabetic drug does this by inhibiting dipeptidyl peptidase 4 (DPP4), a protein that inactivates GLP-1 and GIP.

Vildagliptin can also be combined with other antidiabetic drugs. Perhaps the most common combination is Eucreas, another trade name from Novaris, which is a combination of vildagliptin and metformin. The latter is actually a first-line drug for type 2 diabetes treatment and is one of the most widely used anti-diabetic drugs in the world.

Another popular candidate for combination, sulphonylurea, works by increasing the insulin from the pancreas organ's beta cells. Other anti-diabetic drugs that are commonly joined with vildagliptin include rosiglitazone, brand name Avandia; and pioglitazone, brand name Actos. Both belong to a class of five-membered heterocyclic ring-possessing medications called thiazolidinediones.

Side effects of vildagliptin include constipation, dizziness, fatigue, headaches, nausea, swelling of legs and ankles, tremors, weakness and weight gain. Most of these side effects are caused when the drug is combined with metformin, sulphonylurea or glitazone. Physicians can withhold vildagliptin if the patient is over 75 years of age, has mild heart failure, or is taking angiotensin-converting enzyme (ACE) inhibitors, which are drugs used to treat the aforementioned condition, as well as hypertension.

On 26 September 2007, the European Medicines Agency (EMA) authorized vildagliptin. The European Commission, the executive body of the European Union (EU), then approved the drug on 1 February 2008 for launch in its member nations. Twenty-four days later, the same body approved Eucreas.

Since then, vildagliptin has launched in 37 countries and has been approved in 70 countries. Novaris, however, has not submitted the drug to the United States Food and Drug Administration (FDA). This has placed a halt of the medication's approval in the U.S., since the FDA has called for additional clinical data in light of skin lesions and kidney problems that have appeared in animal studies.

WiseGeek is dedicated to providing accurate and trustworthy information. We carefully select reputable sources and employ a rigorous fact-checking process to maintain the highest standards. To learn more about our commitment to accuracy, read our editorial process.
Discussion Comments
WiseGeek, in your inbox

Our latest articles, guides, and more, delivered daily.

WiseGeek, in your inbox

Our latest articles, guides, and more, delivered daily.